HEPATIQ

Go Beyond Child-Pugh (CP) Scoring before an HCC Intervention

Please visit our booth 324 at SIR 2025 to learn how HEPATIQ® - The Ultimate Liver Test® - can take you beyond Child-Pugh (CP) scoring and provide you a full picture of the health of the liver.  HEPATIQ is FDA cleared and insurance reimbursable.

Liver transplantation (LT) has the greatest cure potential for hepatocellular carcinoma (HCC).  Bridge therapies prior to LT include stereotactic body radiation therapy (SBRT), Yttrium-90 radioembolization (Y90), radiofrequency ablation (RFA), transarterial chemoembolization (TACE) and surgical resection.  The CP score is often used in treatment decision making.  However it is a categorical score which is partly subjective.  It is not a quantitative index of remaining liver function.  

The CP score is determined by assigning points to two liver disease complications (encephalopathy and ascites), and three lab test results (Bilirubin, Albumin and Prothrombin Time/INR).  Each of these five factors are assigned a score of 1 to 3 points.  The total points determine the CP category:  A - Good hepatic function (5-6 points), B - Moderately impaired hepatic function (7-9 points), and C - Advanced hepatic dysfunction (10-15 points).  

HEPATIQ provides an objective quantitative index (PHM) of remaining liver function and a physiologic stage H0 to H5.  PHM outperforms Bilirubin, Albumin and INR in identifying compensated liver disease patients who will likely do well after an intervention despite their liver disease (www.hepatiq.com/publications).

We are offering new customers a 3 month free trial of up to 30 HEPATIQ reports worth $2,850.  There is no obligation to buy.  HEPATIQ uses SPECT imaging to provide physicians with quantitative liver function data not available from any other technique - blood tests, elastography (ultrasound or MR), or even a biopsy.  HEPATIQ is pure software and uses existing equipment, radioisotope, infrastructure and staff.  No capital investment is needed.